Amgen pulls high-price version of Repatha in bid to raise sales

AMGEN said it is pulling the higher-priced version of its cholesterol drug Repatha from the market, an effort to boost sales of the drug. The drug is manufactured n Rhode Island. / BLOOMBERG NEWS FILE PHOTO
AMGEN said it is pulling the higher-priced version of its cholesterol drug Repatha from the market, an effort to boost sales of the drug. The drug is manufactured n Rhode Island. / BLOOMBERG NEWS FILE PHOTO
NEW YORK – Amgen Inc. will pull its higher-priced version of its cholesterol drug Repatha from the market, an effort to boost sales of the drug by offering only a lower-priced version of the product. The move locks in a price cut Amgen announced last year. Effective Dec. 31, the remaining version of the heart…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -

No posts to display